Human secreted phospholipases A2 (sPLA2s) represent novel attractive therapeutic targets and biomarkers in coronary artery diseases (CAD). We have shown that human Group X sPLA2 (hGX sPLA2) is present in atherosclerotic lesions and that hGX sPLA2 modiÀ ed LDL induces foam cell formation. To elucidate whether hGX sPLA2 has a causative role in CAD we have screened the human PLA2G10 gene to identify frequent polymorphisms, and we have examined their possible association with cardiovascular end-points and intermediate inÁ ammatory phenotypes in a large prospective study of patients with CAD (the AtheroGene study). Although no signiÀ cant association was found between the various polymorphisms identiÀ ed and lipids or inÁ ammatory markers, patients carriers of the C allele of the T-512C polymorphism located in the 5' untranslated region showed a decreased risk of recurrent cardiovascular events. Molecular analysis of the only missense variant (R38C) showed its functional relevance as it leads to a profound change in expression and secretion of hGX sPLA2. Objectives -Vascular Cell Adhesion Molecule-1 (VCAM-1) plays a major role in the chronic inÁ ammatory processes involved in vulnerable atherosclerotic plaque development. It has been shown that the technetium-labelled HMC-I derived peptide B2702p bound speciÀ cally to VCAM-1 and allowed the ex vivo imaging of atherosclerotic lesions in WHHL rabbits. However, B2702p targetto-background ratio was suboptimal for in vivo imaging of VCAM-1 expression in atherosclerotic lesions. In order to increase the target to background ratio, ten derivatives of B2702p were synthesized (B2702p-1 to 10). We hypothesized that technetium radiolabelled B2702p derivatives might allow the molecular imaging of VCAM-1 expression in an experimental model of atherosclerosis.
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IDENTIFICATION OF POLYMORPHISMS IN THE GENE ENCODING SECRETED PHOSPHOLIPASE A2 GROUP X AND STUDY OF THEIR ROLE IN CORONARY ARTERY DISEASE. THE ATHEROGENE STUDY
Human secreted phospholipases A2 (sPLA2s) represent novel attractive therapeutic targets and biomarkers in coronary artery diseases (CAD). We have shown that human Group X sPLA2 (hGX sPLA2) is present in atherosclerotic lesions and that hGX sPLA2 modiÀ ed LDL induces foam cell formation. To elucidate whether hGX sPLA2 has a causative role in CAD we have screened the human PLA2G10 gene to identify frequent polymorphisms, and we have examined their possible association with cardiovascular end-points and intermediate inÁ ammatory phenotypes in a large prospective study of patients with CAD (the AtheroGene study). Although no signiÀ cant association was found between the various polymorphisms identiÀ ed and lipids or inÁ ammatory markers, patients carriers of the C allele of the T-512C polymorphism located in the 5' untranslated region showed a decreased risk of recurrent cardiovascular events. Molecular analysis of the only missense variant (R38C) showed its functional relevance as it leads to a profound change in expression and secretion of hGX sPLA2. Objectives -Vascular Cell Adhesion Molecule-1 (VCAM-1) plays a major role in the chronic inÁ ammatory processes involved in vulnerable atherosclerotic plaque development. It has been shown that the technetium-labelled HMC-I derived peptide B2702p bound speciÀ cally to VCAM-1 and allowed the ex vivo imaging of atherosclerotic lesions in WHHL rabbits. However, B2702p targetto-background ratio was suboptimal for in vivo imaging of VCAM-1 expression in atherosclerotic lesions. In order to increase the target to background ratio, ten derivatives of B2702p were synthesized (B2702p-1 to 10). We hypothesized that technetium radiolabelled B2702p derivatives might allow the molecular imaging of VCAM-1 expression in an experimental model of atherosclerosis.
A030
IN VIVO MOLECULAR IMAGING OF VASCULAR CELL ADHESION MOLECULE-1 EXPRESSION IN ATHEROSCLEROTIC PLAQUES
Material and Methods -A mouse model of focal atherosclerotic plaque development induced by left carotid artery ligation in ApoE-/-mice was used. 99mTc-B2702p (n=9) and 99mTc-B2702p-1 -10 (n=3 for each except B2702p-1, n=5, and B2702p-4, n=5) were injected intravenously to the anesthetized animals 3 weeks following the ligation. Whole-body planar image acquisition was performed for 3 hrs with all radiolabelled peptides and SPECT imaging of 6 additionnal mice was also performed with 99mTc-B2702p-1. The animals were then euthanized and the biodistribution evaluated by gamma-well counting of excised organs. The expression of VCAM-1 in the ligated and contralateral arteries was evaluated by immunohistology.
Results -A robust VCAM-1 immunostaining was observed in ApoE-/-mice in the atherosclerotic lesions at the level of the left carotid whereas no VCAM-1 expression was detected in the contralateral carotid. Among the ten evaluated peptides, 99mTc-B2702p-1 exhibited the more favourable properties. By gamma-well counting, there was a signiÀ cant 2.0-fold increase in 99mTc-B2702p-1 left-toright carotid artery activity ratio (2.61±0.61) and a 3.4-fold increase in left carotid-to-blood activity ratio (1.41±0.36) in comparison to 99mTc-B2702p (1.32±0.23 and 0.41±0.09, respectively, P<0.05 for both comparisons). Finally, a higher 99mTc-B2702p-1 activity in the left than in the right carotid was observed by SPECT imaging (33.3±5.8 vs. 25.1±5.3 cpm/mm²/ID, respectively, P<0.05). 
Conclusion
